Bioexa Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.20 M
- Company Age 5 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 114.99%
- Profit Growth 725.70%
- Ebitda 598.18%
- Net Worth 119.91%
- Total Assets 87.69%
About Bioexa Lifesciences
Bioexa Lifesciences Private Limited (BLPL) is a Private Limited Indian Non-Government Company incorporated in India on 07 October 2019 (Five years and four months 5 days old ). Its registered office is in Agra, Uttar Pradesh, India.
The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.20 M, as per Ministry of Corporate Affairs (MCA) records.
Sanjay Prabhakar and Shweta Singh serve as directors at the Company.
Company Details
-
Location
Agra, Uttar Pradesh, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24100UP2019PTC122059
-
Company No.
122059
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
07 Oct 2019
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Kanpur
Industry
Who are the key members and board of directors at Bioexa Lifesciences?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sanjay Prabhakar
|
Director | 07-Oct-2019 | Current |
|
Shweta Singh
|
Director | 07-Oct-2019 | Current |
Financial Performance of Bioexa Lifesciences.
Bioexa Lifesciences Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 114.99% increase. The company also saw a substantial improvement in profitability, with a 725.7% increase in profit. The company's net worth Soared by an impressive increase of 119.91%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Bioexa Lifesciences?
Unlock access to Bioexa Lifesciences's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
-
Novalek Pharmaceutical Private LimitedSanjay Prabhakar is a mutual person
-
Novalek Laboratories LlpSanjay Prabhakar and Shweta Singh are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Bioexa Lifesciences?
Unlock and access historical data on people associated with Bioexa Lifesciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Bioexa Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Bioexa Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.